
UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation
UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation (DE:FRC2) Price & Chart
DE:FRC2 ETF Chart & Stats
- Day’s Range
- EUR 52.37 - EUR 52.98
- 52-Week Range
- EUR 43.13 - EUR 54.38
- Previous Close
- EUR 53.20
- Volume
- 0
- Average Volume (3M)
- 95
- AUM
- 1.82B
- NAV
- 43.52
- Expense Ratio
- 0.20%
- Holdings Count
- 66
- Beta
- 0.56
- Inception Date
- Aug 30, 2013
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 41,360,416
- Standard Deviation
- N/A
ETF Overview
UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation
The UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation, trading under the ticker DE:FRC2, is a compelling investment vehicle designed for those looking to gain comprehensive exposure to the total UK equity market. This ETF, categorized under Size and Style with a focus on the Total Market, offers investors a broad-based niche opportunity to tap into the performance of both large and mid-cap UK companies. By tracking the MSCI United Kingdom Index, the fund provides a diversified portfolio that captures the essence of the UK market's dynamic landscape. It strategically includes various sectors, offering a balanced representation of the UK economy. This makes it an ideal choice for investors seeking to diversify their portfolios with a focus on a developed market known for its stability and growth potential. The capitalisation approach of this ETF ensures that investors benefit from a reinvestment of dividends, potentially enhancing long-term returns. As a UCITS ETF, it adheres to stringent European regulatory standards, offering a high level of transparency and investor protection. Whether you're a seasoned investor or new to the market, the UBS (Lux) Fund Solutions SICAV - MSCI United Kingdom UCITS ETF A- Capitalisation provides a robust platform to capture the full spectrum of the UK equity market.
- Asset Class
- Equity
- Region
- Europe
- Issuer
- UBS
- Index Tracked
- MSCI United Kingdom
- Ticker Symbol
- DE:FRC2
DE:FRC2 ETF News


AstraZeneca plc ($GB:AZN) announced an update on their ongoing clinical study. Study Overview: AstraZeneca’s GRACE-DE study, officially titled “Prospective, Observational, Multicenter, and Multicohort Study of Patients With Gastric Cancer Initiating




DE:FRC2 ETF FAQ
What was DE:FRC2’s price range in the past 12 months?
What is the AUM of DE:FRC2?
Is DE:FRC2 overvalued?
How many shares outstanding does DE:FRC2 have?
DE:FRC2 ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| HSBAHsbc Holdings Plc (UK) | 9.68% |
| SHELShell plc (UK) | 8.97% |
| AZNAstraZeneca plc | 8.87% |
| RRRolls-Royce Holdings | 4.66% |
| ULVRUnilever Plc (UK) | 4.55% |
| BATSBritish American Tobacco (UK) | 3.94% |
| BPBP p.l.c. | 3.75% |
| GSKGlaxoSmithKline plc (UK) | 3.26% |
| RIORio Tinto (LSE:RIO) | 2.74% |
| NGNational Grid (Uk) | 2.66% |
| Total | 53.08% |









